Application of dendritic cell combined with cytokine-induced killer cell in lung cancer treatment

A cell and lung cancer technology, applied in the application field of dendritic cells combined with cytokine-induced killer cells in the treatment of lung cancer, can solve the problem that there is no data showing the effect of chemotherapy combined with immunotherapy in patients with advanced non-cellular lung cancer

Inactive Publication Date: 2012-02-22
SHANGHAI CHEST HOSPITAL
View PDF2 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] However, to date there are no data showing the effect of chemothera...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of dendritic cell combined with cytokine-induced killer cell in lung cancer treatment
  • Application of dendritic cell combined with cytokine-induced killer cell in lung cancer treatment
  • Application of dendritic cell combined with cytokine-induced killer cell in lung cancer treatment

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0053] Embodiment 1, patient and dosing regimen

[0054] According to the WHO standard, the patient had histologically confirmed non-small cell lung cancer, and the serum CEA level (measured by conventional chemiluminescent method) was 6-394 ng / ml (normal value: 5 ng / ml). Peripheral blood was drawn from patients who were positive for HLA-A2 confirmed by flow cytometry, and mononuclear cells were isolated. The patient's bone marrow, liver and kidney functions were normal. The patient had no autoimmune diseases, no brain metastases, and no acute or chronic infectious diseases. From August 2004 to October 2005, 28 patients with III B-IV NSCLC were enrolled. Randomly enter the chemotherapy group or immunochemotherapy group. The size of the lesion was evaluated by CT every 4 weeks. Chemiluminescence was used to evaluate the CEA value before and after each treatment. Toxic reactions were in accordance with NCI (2.0) standards. This study was approved by the Ethics Committee of...

Embodiment 2

[0063] Example 2, Preparation of DC and Induction of CIK Production

[0064] Preparation of DC

[0065] In the immunotherapy group, 100 ml of the patient's own peripheral blood was extracted, and the mononuclear cell layer was separated by the Ficoll-Paque density separation method, suspended in the X-VIVO culture medium containing 1% (v / v) autologous serum, and placed in the culture medium. In the dish, adjust the cell concentration to 5×10 6 cells / ml and cultured in a 37°C incubator. After 4 hours, adherent cells (adherent cells) were reserved for DC culture, and non-adherent cells were reserved for CIK cell culture. Adherent cells were suspended with X-VIVO (cell concentration 2×10 6 / ml), add 1000 units (U) / mL of GM-CSF (purchased from Leukomax; Novartis International AG, Basel, Switzerland), 500 units / mL of recombinant IL-4 (purchased from Strathmann Biotec AG, Hannover, Germany) ) to culture DC.

[0066] Peptide sensitization: CEA peptide, the sequence is YLSGANLNL ...

Embodiment 3

[0070] Embodiment 3, administration characteristic

[0071] The characteristics of the patients after the immunochemical group are shown in Table 2. The average amount of injected DC was 8.1±2.5 (10 6 ), the average amount of CIK is 13.3±3.5 (10 8 ) (single injection volume). Serum CEA levels are elevated when they are 25% above baseline. Decline was defined as a 25% decrease from baseline. Otherwise, it is considered stable. In the immunochemotherapy group, CEA levels decreased in 3 patients (21.4%). Stable in 9 patients (64.2%). Grade 1-3 skin toxicity occurred in 9 patients (64.2%), and grade 1-4 non-infectious fever occurred in 10 patients (71.4%).

[0072] Table 2. Characteristics of patients in the immunochemistry group

[0073]

[0074]

[0075]Among them, the grading of skin toxicity follows the National Cancer Institute common toxicity criteria v.2.0 grading system standard.

[0076] Non-infectious fever was graded according to the National Cancer Insti...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to an application of dendritic cells combined with cytokine-induced killer cells in lung cancer treatment. The invention prepares sensitized DC cells and CIK cells; the two cells are transfused back to patients with lung cancer, which can effectively prolong the survival time of the patients; and the toxic and side effect is low.

Description

technical field [0001] The invention belongs to the fields of biopharmaceuticals and immunology; more specifically, the invention relates to the application of dendritic cells combined with cytokine-induced killer cells in the treatment of lung cancer. Background technique [0002] Lung cancer is a disease that seriously threatens human health, among which the mortality rate of non-small cell lung cancer occupies the first place. At the time of diagnosis, most patients are already advanced (stage IIIB-IV) and cannot be treated surgically. Patients with stage IIIB-IV non-small cell lung cancer can only receive chemotherapy-based treatment. The side effects of chemotherapy include: bone marrow suppression, gastrointestinal reactions and infectious diseases. Given the limitations of chemotherapy, a novel treatment modality needs to be developed. [0003] Among different treatment modes, immunotherapy has attracted increasing attention because of its targeted killing of tumor...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K35/12A61K35/14C12N5/0784C12N5/078A61P35/00A61K35/15A61K35/17
Inventor 钟华韩宝惠钟润波
Owner SHANGHAI CHEST HOSPITAL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap